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Background/Aims: Augmenter of liver regeneration (ALR), a protein synthesized and stored in hepatocytes, is associated 
with mitochondria, and possesses sulfltydryJ oxidase and cytochrome c reductase activities. We sought to determine the 
effects of ALR depletion in hepatocytes by antisense oligonucleotide transfection. 
Methods: Rat hepatocytes in primary culture were transfected with antisense oligonucleotide for ALR mRNA (ALR-
AS) or scrambled oligonucleotide. Various analyses were performed at times up to 24 h after transfection. 
Results: Treatment with ALR-AS caused a decrease in ALR mRNA, cellular depletion of ALR protein primarily from 
mitochondria, and decreased viability. Flow cytometric analysis of ALR-AS-transfected hepatocytes stained with annexin-
Vcy3 and 7-aminoactinomycin D revealed apoptosis as the predominant cause of death up to 6 h; incubation beyond this 
time resulted in necrosis in addition to apoptosis. ALR-AS-transfection caused release of mitochondrial cytochrome c, 
activation of caspase-3, profound reduction in the ATP content, and cellular release of LDH. Inhibition of caspase-3 inhib-
ited the early phase of ALR-AS-induced death but not the late phase that included ALR and LDH release. 
Conclusions: These results suggest that ALR is critically important for the survival of hepatocytes by its association with 
mitochondria and regulation of ATP synthesis. 
© 2008 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. 
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1. Introduction 
Augmenter of liver regeneration (ALR), originally 
identified in the soluble fractions of hypertrophic rat liv-
ers [1-3], was purified from weanling rat liver [4,5], and 
its gene cloned in rat, mouse and human [6,7]. The mito-
genic and anti atrophic activities of native and cloned 
ALR were demonstrated in partially hepatectomized 
rats [1] and in dogs with portacaval shunt [2-4,6,7]. 
ALR also inhibits the lytic activity of hepatic natural 
killer cells [8,9], which is critical for unabated liver 
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regeneration [10]. Presence of hepatotrophic activity in 
weanling and regenerating [1-3,11] but not in the 
unmodified adult animal livers [UJ suggested that 
ALR is not synthesized by the latter. However, we 
found that ALR mRNA and protein are expressed sim-
ilarly in weanling and unmodified adult rat livers in 
hepatocytes [12]. Together, these observations suggest 
that ALR may have multiple intracellular and extracel-
lular functions. Indeed, results of experiments with short 
form (15 kDa) [13-15] differ substantially from that with 
long form (22 kDa) ALR [12J. 
The C-terminus of mammalian ALR is 40% identical 
with ER VI P (essential for respiration and vegetative 
growth I protein) [16J, product of the Saccharomyces 
cerevisiae gene ERVI [17,18J. ERVlp and ALR are fla-
vin-containing sulfhydryl oxidases localized in the mito-
chondrial intermembrane space [19-21]. ERVlp is 
necessary for the growth and survival of the yeast as 
indicated by complete loss of mitochondrial genome 
and death upon disruption of the ER VI gene [17 ,22J. 
We hypothesized that in hepatocytes, ALR might play 
role functionally equivalent to ERVlp. Transfection of 
primary hepatocytes with antisense oligonucleotide for 
ALR mRNA (ALR-AS) led to mitochondrial and cellu-
lar depletion of ALR, profound loss of ATP, mitochon-
drial release of cytochrome c, cellular release of LDH 
and apoptotic/necrotic death of hepatocytes. 
2. Materials and methods 
2.1. Preparation of hepatocytes 
Hepatocytes were prepared as described previously [23J, and sus-
pended (0.25 x 106 cells/ml) in William's medium E supplemented with 
2 mM L-glutamine, penicillin/streptomycin, 10% FBS, and 10-6 M 
insulin. Cells were plated at a density of 0.063 x 106/cm2, the medium 
renewed 3 h later, and the cells used following overnight incubation. 
2.2. Transfection with ALR-AS 
The sequence of phosphorothioated ALR-AS-oligonucleotide com-
plementary to nucleotide sequence 24-43 downstream from the start 
codon of ALR mRNA was 5'-GACTGCCGCGAGGGAAACCT-3'; 
the sequence of scrambled oligonucleotide was 5'-ACTGACAG 
ATCGGGCAAGCC-3'. To increase stability [24J, five bases of the 
oligonucleotides at both 5' and 3' ends were replaced with 2'-O-meth 
RNA. internal dCs were replaced with 5-Me-dC. FAM-Iabeling was 
added at the 5' end and a hairpin loop was introduced at the 3' end. Lipo-
fectamine-2000 (8 J.ll/ml; Invitrogen) or the oligonucleotides (final con-
centration 1.2 ~iMF in lipofectamine-2000 were incubated separately in 
200 fll of Opti-MEM medium (GibcoBRL, Grand Island, NY) for 
30 min. Eight hundred microliters of Opti-MEM was added and the 
combined solution was overlaid onto the cells. After 5 h, I ml of Wil-
liam's medium E containing 20% FBS was added to each well. The effi-
ciency of transfection was determined by fluorescence microscopy. 
2.3. Live cell imaging 
Collagen-coated (10%) 40-mm coverslips with cultured hepatocytes 
were inserted in a FCS2 closed heated (37°C) live cell chamber (Biop-
tics, Bulter, PAl, which was placed on a Nikon TE300 inverted micro-
scope (Melville, NY). Media were perfused through the chamber at a 
rate of 0.5 ml/h. Using a 40x dry objective, five stage positions were 
imaged with transmitted light every 3 min. The acquired images were 
processed with Metamorph software (Universal Imaging Corporation, 
Downingtown, PAl. 
2.4. Flow cytometric analysis 
The medium containing detached cells was aspirated, and the 
attached cells were harvested using 0.025'10 trypsin. The two cell frac-
tions were pooled, washed twice with PBS by centrifugation at 450g 
(10 min, 4°C), fixed in ice-cold 70"/., ethanol for 3 h, and washed with 
Ca2+-/Mg2+-free HBSS containing 1% BSA. The cells were suspended 
in 0.5 ml of propidiurn iodide solution (50 J.lg/ml propidium iodide. 
I mg/ml sodium citrate, 100 flg/ml RNase I and 0.1% Triton X-IOO). 
After 30 min at 37°C, the cells were analyzed by flow cytometry in a 
fluorescence-activated cell sorter (Epics XL.MCL, Beckman-Coulter) 
using EXP032 software. 
To distinguish a poptosis and necrosis, the cells were harvested (see 
above), washed with PBS, and suspended in buffer A (10 mM Hepes, 
140 mM NaCI and 2.5 mM CaCI2, pH 7.4) at I x 106 cells/ml. 
Annexin-Vcy3 (4 flg/ml) and 7-aminoactinomycin D (7-AAD) (5 flg/ 
ml) were added to 100 J.lI of the cell suspension. After gentle mixing, 
the suspension was incubated at room temperature for 15 min in dark, 
followed by the addition of 400 III of buffer A. Flow cytometry was 
performed within I h. 
2.5. Determination of viability, ATP and cell death 
markers 
The viability was determined by the MIT assay [25]. The cells were 
harvested as described above for A TP determination using Cell Viabil-
ity Assay Kit-ATP (Sigma Chemical Co., St. Louis, MO). Cytosolic 
cytochrome c was measured using the Quantikine murine immunoas-
say kit (R&D Systems, Minneapolis, MN). Caspase-3 activity was 
determined using caspase fluorescent assay kit (BD Biosciences-Clon-
tech, San Jose, CAl. LDH was measured using spectrophotometric 
assay kit (Stanbeo Laboratory, Boerne, TX). 
2.6. Determination of ALR mRNA and protein 
After treatments, the culture medium was aspirated and centri-
fuged to separate detached cells. ALR in the medium was measured 
by ELISA [12]. The attached cells were harvested by trypsin treatment; 
the two cell fractions were combined and centrifuged (lOOOg/5 min). 
Total RNA was extracted from the cells and analyzed for ALR mRNA 
by semiquantitative RT-PCR as described previously ;12]. 
For mitochondrial preparation, hepatocytes (pooled attached and 
detached fractions) were homogenized in 2 mM Hepes. pH 7.4, contain-
ing 0.22 M mannitol, 70 mM sucrose, 0.1 mM EDTA, and 1% fatty 
acid-free BSA. The homogenate was centrifuged at 800g for 10 min, fol-
lowed by centrifugation of the supernatant at II ,000g for 15 min. The 
pellet was washed and suspended in RIPA buffer (Santa Cruz Biotech-
nology, Santa Cruz, CAl containing 25 fll/ml protease inhibitor cock-
tail (Sigma) and 0.5 mM phenylmethylsulfonylfluoride. After 15 min 
on ice, the lysate was centrifuged (I0,OOOg/1O min); ALR in the super-
natant was determined by ELISA and Western blot analysis [12]. 
For cytosolic preparation, hepatocytes were homogenized in 
10 mM Tris-HCI, pH 8.0, containing 60 mM KC1, I mM EDTA, 
100 flM PMSF and 25 fll/ml protease inhibitor cocktail. After 10 min 
on ice, NP40 (25 J.ll/ml) was added; the homogenate was vortexed vig-
orously for 10 s, centrifuged (2500 rpm/4 min) followed by centrifuga-
tion of the supernatant at 14,000 rpm for 5 min. ALR in the 
supernatant was quantified by ELISA [12]. 
2.7. Statistical analysis 
Statistical significance was determined by ANOVA-Duncan analy-
sis using SPSS program. A p value of 0.05 was considered statistically 
significant. 
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Fig. 1. Effect of rrALR on DNA synthesis in hepatocytes. (A) 
Coomassie blue staining and Western blot analysis of recombinant rat 
ALR (rrALR) using anti-rrALR antibody show a single band with 
molecular weight of about 22 kDa. (B) Hepatocytes were stimulated 
under serum-free condition with 1 Jlg/ml ALR or 10 nglml TGF-<x for 24 
and 48 h. DNA synthesis was then measured by eH]thymidine incorpo-
ration assay. 'p < 0.001 vs control. 
3. Results 
3.1. Effect of recombinant rat ALR (rrALR) on 
hepatocytes 
Fig. lA shows purity of the rrALR by Coomassie 
blue staining and Western blot analysis [12]. The rrALR 
did not affect the DNA synthesis in hepatocytes at either 
24 h or 48 h (Fig. lB); in contrast, TGF-ct caused a 
robust increase in the DNA synthesis at both points. 
The lack of response of rat hepatocytes to 22 kDa-
rrALR is consistent with absence of ALR-specific recep-
tors in them [12J. 
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Fig. 2. Time-course of ALR-AS-induced loss of cellular ALR and 
viability. Hepatocytes were transfected with ALR·AS or scrambled 
oligonucleotides as described in Section 2. At indicated time points, the 
release of ALR into extracellular medium (A), cell-associated ALR (B), 
and cell viability (C) was measured. Results are means ± SD of triplicate 
determinations from a representative experiment. 'p < 0.05 vs control; 
"p < 0.01 vs control; "'p < 0.005 vs control; #p < 0.001 vs control. 
3.2. Effect of ALR-AS on cellular ALR and viability 
ALR-AS-treatment caused time-dependent loss of 
ALR from cells with concomitant increase in the extra-
Fig. 3. Morphology and live cell images of hepatocytes after transfection with ALR-AS. Hepatocytes were transfected with ALR-AS or scrambled 
oligonucleotides as described in Section 2. (A) Phase contrast images of ALR-AS-treated, control and scrambled ODN-treated cells at 24 h are shown. 
(B) Cells were harvested at 24 h after transfection with ALR-AS or scrambled OON and subjected to flow cytometry after labeling with propidium iodide. 
The subGO phase, GO/Gl, S, and G2/M phases of the cell cycle were analyzed by diploid staining profiles and ModFit software program. Forward and side 
light scatter characteristics were used to exclude cell debris (size and granularity) from the analysis. The percentage of cell aggregates (doublets) and 
other background were also eliminated using peak vs integral gating of cells. C, GO subphase; D, GO/GI phase; E, S phase; and F, G2/M phase. Values for 
the percentage of cells in various phases with standard deviations from three.independent experiments are presented in the text. (C) Images of ALR-AS· 
treated, control, and scrambled ODN-treated hepatocytes were acquired every 3 min as described in Section 2. Representative images of hepatocytes 
acquired at the start of the experiment and at about 5.5 h (ALR.AS-treated), and 12 h (control or scrambled OON-treated) are shown. 
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cellular medium (Fig. 2A and B). This effect was associ-
ated with progressive loss of viability (Fig. "lC). The rel-
atively high basal level of ALR release without apparent 
loss from cultured hepatocytes is consistent with our 
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previous report [12]. Phase contrast microscopy showed 
rounding and detachment of hepatocytes by ALR-AS 
but not scrambled-ODN treatment (Fig. 3A). Flow 
cytometric cell cycle analysis (Fig. 3B) showed that 
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Fig. 4. Effect of ALR-AS on ALR mRNA and protein. (A) mRNA from 
the whole cells of ALR-AS-treated (A), control (C) and scrambled ODN-
treated (S) hepatocytes were extracted after 12 h incubation period. RT-
peR was performed as described in Section 2. The expression of JJ-actin 
(mRNA control) is shown to indicate equal loading. (B) The whole 
homogenate, mitochondria and cytosol were analyzed for the ALR levels 
by ELISA after various treatments for 12 h. Results shown are 
means ± SD of triplicate determinations from a representative experi-
ment. 'p < 0.05 vs control; "p < 0.025 vs control. (C) Protein from the 
mitochondria of ALR-AS-treated (A), control (C) and scrambled ODN-
treated (8) hepatocytes was extracted after 12 h incubation and Western 
blot analysis were performed as described in Section 2. Porin expression 
is shown to indicate similar loading of mitochondrial protein. 
35% and 33% of ALR-AS-transfected hepatocytes were 
in GO/Gl and G2/M phases, respectively, as compared 
with 20% and 70% control cells, indicating strong 
growth arrest and increased apoptosis [26]. Scrambled 
ODN-treatment induced only marginal changes. Con-
tinuous acquisition of the live cell images of ALR-AS-
transfected hepatocytes showed beginning of their 
shrinking and detachment within 2-3 h. In the image 
captured at 5.5 h (Fig. 3C), several hepatocytes exhib-
ited apoptotic characteristics (rounding, loose contact 
with neighboring cells and surface, and cytoplasmic 
blebs). Only few scrambled-ODN-treated hepatocytes 
showed evidence of morphological changes indicative 
of apoptosis at 12 h. Together these results suggest that 
ALR is essential for physiological function and survival 
of hepatocytes. 
We determined ALR mRNA and protein levels at 
12 h time point considering near-maximal loss of ALR 
and viability (Fig. 2). ALR-AS-treatment caused nearly 
complete loss of ALR mRNA, (Fig. 4A). There was sub-
stantial loss of ALR from ALR-AS-treated cells when 
the whole cell homogenate was analyzed (Fig. 4B); 
tracking the subcellular distribution showed that cellular 
ALR loss was predominantly from the mitochondrial 
compartment. The decrease in the cytosolic ALR was 
modest, but the loss of mitochondrial ALR was very 
strong both by ELISA (Fig. 4B) and Western blot anal-
ysis (Fig. 4C). 
Whether ALR-AS causes necrosis secondary to apop-
tosis was determined in hepatocytes labeled with 
annexin-Vcy3 [marker of phosphatidylserine externaliza-
tion during apoptosis [27,28], and 7-AAD [permeant 
marker of presumptively necrotic cells [29]. At 24 h of 
ALR-AS treatment, apoptotic cells (Fig. SA, lower right 
quadrant) increased threefold (Fig. 5B), while the num-
ber of cells in late apoptosis/necrosis phase (upper right 
quadrant) (Fig. SA) increased fourfold (Fig. SB). Rela-
tively small changes were seen in scrambled ODN-trans-
fected cells (Fig. SA and B). 
3.3. Apoptotic signaling, ATP loss and LDH release 
To evaluate more precisely the role of apoptosis in 
ALR-AS-treated hepatocytes, we quantified cytosolic 
cytochrome c and caspase-3-like activity. Both cytosolic 
cytochrome c and caspase-3-like activity increased 
robustly between 6 and 12 h in ALR-AS-treated cells, 
with peak values at 12 h (Fig. 6). Scrambled ODN-trea-
ted hepatocytes showed a smaller progressive increase in 
cytosolic cytochrome c between 6 and 24 h, and rela-
tively small increase in the caspase-3-1ike activity. The 
ATP content of ALR-AS-treated cells decreased pro-
gressively between 3 hand 24 h, with the sharpest 
decrease between 3 and 6 h (Fig. 7 A). Scrambled 
ODN-treated cells showed a small progressive decrease, 
while in control cells ATP content was unchanged. LDH 
was released at 12 h and later from ALR-AS-transfected 
cells (Fig. 7B), with no change in scrambled ODN-trea-
ted cells. Together these results confirm that both 
apoptosis and necrosis contribute to the loss of ALR-
AS-treated hepatocytes. 
Next we determined the time-course of the loss of 
ALR and ATP from mitochondria (Fig. 8). Within I h 
after ALR-AS treatment, there was substantial loss of 
mitochondrial ALR (maximal at 6 h), followed by 
ATP loss with significant decrease at 3 h and maximal 
between 12 and 24 h. 
Finally, we determined if caspase-3 inhibition blocks 
ALR-induced apoptosis/necrosis of ALR-treated hepa-
tocytes. Pretreatment and presence of DEVD-fmk dur-
ing ALR-AS-treatment inhibited depletion of ALR, 
and LDH release till 6 h (Fig. 9A-C) and inhibited sub-
stantially the loss of viability till 12 h (Fig. 9D). But 
after this, the loss of ALR, LDH and viability was 
nearly similar in incubations without and with DEVD-
fmk (Fig. 9). These results suggest that the initial phase 
of ALR-AS-induced cells death (apoptotic) is inhibited 
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Fig.5. Flow cytometry ofannexin-Vcy3- and 7-AAD-labeled hepatocytes. Control cells and cells treated with scrambled ODN or ALR-AS were harvested 
at 24 h and labeled with annexin-VcyJ and 7-AAD. (A) Flow cytometry was then performed as described in Section 2; a representative profile is shown. El, 
E2, E3 and E4 represent cell debris, necrotic cells (annexin-Vcy3-positivel7-AAD-positive), normal cells (annexin-VcyJ-negativel7-AAD-negative) and 
apoptotic cells (annexin-VcyJ-positive/7-AAD-negative), respectively. (B) Histogram showing percentage of normal cells, and cells in early apoptotic and 
late apoptotic/necrotic phases. For each measurement, 10,000 events were counted. Each value is average of duplicate determinations from two separate 
experiments ± SD. 'p < 0.01 vs control; "p < 0.05 vs control; "'p < 0.005 vs control. 
by caspase-3 inhibition, but not the continued ALR loss 
leading to necrosis. 
4. Discussion 
In this report we present evidence supporting ALR's 
role as an intracellular survival factor for hepatocytes. 
The 22 kDa rrALR did not stimulate DNA synthesis 
in rat hepatocytes unlike in human hepatocytes with 
recombinant human ALR dimer (rhALR) [13,15]. On 
a molar basis hepatocyte DNA synthesis stimulated by 
rhALR was much stronger than that by the powerful 
hepatocyte mitogens EGF and TGF-cx [13]. The effects 
of rhALR and the most potent hepatocyte mitogen 
HGF on the DNA synthesis in human hepatocytes were 
also comparable [15]. The discrepancy may be because 
we used the entire rrALR molecule (198 amino acids; 
starting sequence MAAPS-) and not the short ALR 
molecule (125 amino acids) with starting sequence of 
MRTQ- ("M" representing amino acid "74" in native 
ALR) [7]. In previous studies [13,15], dimer of the 
human ALR C-terminus sequence starting with 
MRTQ- ("M" representing amino acid "71" in native 
ALR [7]) expressed in the bacterial system was used. 
The monomer (short ALR) has mw of about 15 kDa 
while the cDNA for native ALR encodes a protein with 
mw of about 22 kDa [6,7]. The crystal structure [30] and 
the FAD-linked sulfhydryl oxidase and cytochrome c 
reductase activities of ALR [31] were deduced based 
on the assumption that it is present as a dimer of the 
short ALR. Unlike the rat and mouse ALR monomers, 
each 15 kDa subunit of human ALR contains two addi-
tional nonconserved free cysteine residues (C74 and 
C85) [31]. Again whether the long human ALR per-
forms the same function is unclear [31]. However, we 
note that both the full-length 22 kDa and 15 kDa car-
boxy terminal portion of the ERVI protein, which con-
tains the conserved CXXC motif, were found to bind 
FAD and perform the sulfhydryl oxidase function [19]. 
Interestingly, the full-length ERVI protein (22 kDa/ 
189 amino acid residues), but not its carboxy terminal 
15 kDa domain that forms dimer [19], contains leader 
sequence for import into mitochondria, and thus the 
N-terminal domain is clearly required for mitochondrial 
translocation of ERVlp [32]. Putative targeting 
sequences for mitochondria have also been found in 
the homologous mammalian proteins [32]. ALR is colo-
calized with GF AP in neurons in all brain regions, spe-
cifically in the nucleus and the external envelope of 
mitochondria; Western blot analysis demonstrated at 
least 2 dimers, which under reducing condition migrated 
as two bands with MW of 21 and 23 kDa [33]. The rat 
ALR was found to exist as high molecular weight 
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Fig. 6. Effect of ALR-AS on cytochrome c release and caspase-3-like 
activity. Cells were treated with ALR-AS, Iipofectamine carrier (control) 
or scrambled OON for indicated time periods. Mitochondrial release of 
cytochrome c (A) and caspase-J..like activity (8) were determined as 
described in Section 2. Results are means ± SO of triplicate determina-
tions from a representative experiment. 'p < 0.05 vs control; "p < 0.01 
vs control; '''p < 0.001 vs control. 
species (about 38-42 kDa) and can very well be the 
dimers of the full-length ALR [12J. A 15 kDa ALR iso-
form was reported to be present in the human cancer cell 
line HepG2 [14], but whether it dimerises before eliciting 
biological actions is not known. 
Transfection of rat hepatocytes with ALR-AS 
decreased their viability profoundly due to apoptosis 
and necrosis. Significant release of cytochrome c, but 
not of LDH, at 6 h indicates that apoptosis is a primary 
mechanism of cell death at this time point. Thereafter, 
the release of LDH increased suggesting that necrosis 
was a major cause of cell death after 6 h. In the late 
stages of apoptosis also cell membrane may become per-
meable thus allowing the release of LDH [34-36J. The 
involvement of both cell death processes was confirmed 
by the presence of annexin-5cy3-positive/7-AAD-nega-
tive and annexin-5cy3-positive/7-AAD-positive cells 
after ALR-AS treatment. While ALR depletion caused 
apoptosis and necrosis of hepatocytes, interestingly, 
only the apoptotic phase of cell death was strongly but 
not completely inhibited by caspase-3 inhibition. 
DEVD-fmk inhibited but did not prevent ALR loss as 
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Fig. 7. Effect of ALR-AS on the ATP content and LOH release in 
hepatocytes. Cells were treated with ALR-AS, PBS or scrambled ODN 
for indicated time periods, and cellular ATP content (A) and release of 
LDH (8) were measured as described in Section 2. Results are 
means ± SD of triplicate determinations from a representative experi-
ment. 'p < 0.05 vs control; "p < 0.001 vs control. 
well as LDH release from ALR-AS-treated cells. Thus 
the necrotic phase of ALR depletion-induced cell death 
seems to be independent of prior apoptosis. Also cas-
pase-independent apoptosis at early times (compare 
Figs. 6B and 9D) [37] may not be ruled out. A small 
effect of the scrambled-ODN observed at late time 
points might be nonspecific as these effects are not 
accompanied by any cellular or mitochondrial ALR loss 
compared to the control. 
Depletion of ATP in ALR-AS-transfected hepato-
cytes suggests possible association of ALR with mito-
chondrial function. Mitochondria playa critical role in 
apoptosis, which cannot occur in the setting of cellular 
ATP depletion [38-43]. Both an apoptosis-dependent 
increase in ATP consumption and a separate decrease 
in ATP synthesis may contribute to the lethal ATP 
depletion, global loss of cellular integrity, and necrosis 
[44] of ALR-AS-treated hepatocytes. In support of this 
supposition, ERVIP is shown to be essential for the bio-
genesis of mitochondria [17,22,32], normal mitochon-
drial morphology and stable maintenance of 
mitochondria in S. cerevisiae [16,45]. Disruption of the 
ERV-J gene results in complete loss of mitochondrial 
genome and death of the yeast following a few rep1ica-
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Fig. 8. Effect of ALR-AS on mitochondrial ALR and ATP. Cells were 
treated with ALR-AS, PBS or scrambled ODN for indicated time 
periods. Mitochondria were then prepared, and their ALR (A) and ATP 
(B) contents were measured. Results are means ± SD of triplicate 
determinations from a representative experiment. 'p < 0.05 vs control; 
"p < 0.01 vs control; "'p < 0.005 vs control; #p < 0.001 vs control. 
tions [22]. Thus the significant association of ALR with 
mitochondria and its progressive loss that preceded 
mitochondrial ALR depletion and cytochrome c release 
during treatment with ALR-AS are consistent with the 
notion that ALR, like ERV-IP, might regulate oxidative 
phosphorylation, which is critical for the function and 
survival of the cells. In intact rats, ALR modulates 
hepatocyte mitochondrial function by increasing both 
nuclear-encoded mitochondrial transcription factor A 
and the oxidative phosphorylation capacity of the liver 
[46]. It is well known that a number of hepatic ally active 
Fig. 9. Ellect of caspase-3 inhibitor DEVD-fmk on ALR release and 
cellular ALR, LDH release and viability of hepatocytes during ALR-AS 
treatment. Cells preincubated with 5 I'M DEVD-fmk or carrier for 
30 min. The medium was aspirated and the cells were then treated with 
scrambled ODN or ALR-AS (without and with DEVD-fmk) as described 
in Section 2. At indicated time points, ALR release in the medium (A), 
cellular ALR (B), extracellular release of tDH (C) and cell viability (D) 
were determined. Results are means ± SD of triplicate determinations 
from a representative experiment. 'p < 0.05 vs control; "p < 0.01 vs 
control; "'p < 0.001 vs control; #p < 0.005 vs control; ##p, 0.05 vs 
DEVD-fmklALR-AS; ###p < 0.005 vs DEVD/ALR-AS. 
mediators have no distinct effect in hepatocytes, but eli-
cit the release of secondary mediators from nonparen-
chymal cells. Indeed, our preliminary data (not shown) 
indicate that rat Kupffer cells specifically bind radioio-
dina ted 22 kDa-rrALR. These data provide both a con-
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vincing posItive control for the undetectable binding 
seen in hepatocytes, and a mechanism for ALR-elicited 
hepatocyte-targeted mediator release from this nonpa-
renchymal population. 
mRNA levels were almost completely reduced and cellu-
lar and the mitochondrial release of ALR protein was 
significantly increased in ALR-AS-treated cells suggest-
ing that the depletion of ALR from mitochondria is 
associated with hepatocyte death. Although ALR and ERV-J are essential for the sur-
vival of hepatocytes and S. cerevisiae, respectively, a 
major difference is that ALR is abundantly expressed 
in hepatocytes [12], but the expression of ERV-J is very 
low in the yeast [45). Despite the low level of ER V-I 
expression, null mutation in the gene in the haploid 
yeast strain stopped their replication after 3-4 days 
[17]; it was suggested that this effect was due to high 
in vivo stability of the ERV-I mRNA and protein. 
Lisowsky [21), using expression of the ERVI gene under 
the GAU-JO promoter, found complete loss of mito-
chondrial genome after the promoter was shut off. The 
cells grew for a limited time under these conditions, 
but showed arrest in cell-division cycle as the terminal 
phenotype suggesting the essential requirement but sta-
bility of the ERVI mRNA and protein. The ALR 
A 
In summary, our results indicate a fundamental role 
of ALR in the survival of primary hepatocytes. Whether 
the death caused by the inhibition of its synthesis and 
specific release from the mitochondria has clinical rele-
vance needs further investigation. Based on the results 
presented herein, we propose that there is a dynamic 
exchange between the mitochondrial and newly synthe-
sized and post-translationally modified cytosolic ALR 
(Fig. 10). Inhibition of ALR synthesis leads to decreased 
uptake but does not stop its mitochondrial release. This 
results in reduced ATP synthesis, mitochondrial injury, 
release of cytochrome c and apoptosis. Progressive 
depletion of ALR and further decrease in ATP causes 
necrosis, which is independent of caspase-mediated 
apoptotic phase. 
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Fig. 10. Schematic representation of ALR-AS-induced death of hepatocytes. (A) In physiology, ALR is constitutively synthesized and post-translationally 
modified. The modified ALR is transported into mitochondria and is involved in A TP synthesis (oxidative phosphorylation). ALR uptake and release by 
mitochondria is a dynamic process. The modified (and unmodified) ALR is constitutively released by the cells for actions at distant sites. (B) Upon 
inhibition of ALR synthesis by ALR-AS transfection, uptake bnt not the release of ALR by mitochondria (and the cells) is prevented. This leads to 
inhibition of A TP synthesis, release of cytochrome c, activation of caspase-3 and apoptosis. Further reduction in ALR levels causes profound loss of A TP, 
loss of cell membrane integrity (LDH release) and necrosis. M, mitochondria; PTM, post-translational modification; CytC, cytochrome c; cas-3, caspase-
3; aCas-3, activated caspase-3. Other organelles such as nucleus, endoplasmic reticulum, etc. are not shown for clarity. 
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